Biogen Idec Australia today announced that the Therapeutic Goods Administration (TGA) has approved Eloctate [efraloctocog alfa (rhu)], the first long-acting clotting factor for the treatment of haemophilia A (congenital Factor VIII deficiency). Eloctate is indicated for the control and prevention of bleeding episodes, routine prophylaxis (preventative) and perioperative management (surgical prophylaxis) in adults and children (aged 12 years or over) with haemophilia A.1

“The approval of our long-acting therapy Eloctate marks the first significant treatment advance in haemophilia A in more than 20 years,” said Biogen Idec Australia Managing Director Michael Cloonan. “As a company deeply committed to improving the lives of people with haemophilia, we are excited to bring this important innovation to those living with haemophilia A.”

For more details, go to: http://www.firstwordpharma.com/node/1222018?tsid=1#axzz36DFesl7f